Treatment strategies for unresectable locally advanced non-small cell lung cancer in the real-life ESME cohort
Lung cancer is the most frequent cancer worldwide, and is associated to 1.6 million annual deaths [1]. Among the different histological types of lung cancer, non-small cell lung cancer (NSCLC) is the most common (80 –85%). Stage III, locally-advanced disease is diagnosed in about one third of patients with a diagnosis of lung cancer. In such situations, radical resection is generally not possible because tissues adjacent to the primary tumor or lymph nodes are invaded by tumor cells [2,3].
Source: Lung Cancer - Category: Cancer & Oncology Authors: Nicolas Girard, Maurice Perol, Ga ëtane Simon, Clarisse Audigier Valette, Radj Gervais, Didier Debieuvre, Roland Schott, Xavier Quantin, Bruno Coudert, Hervé Lena, Matthieu Carton, Mathieu Robain, Thomas Filleron, Christos Chouaid Source Type: research